329 results
8-K
EX-3.2
IMGN
Immunogen, Inc.
12 Feb 24
Termination of a Material Definitive Agreement
7:52am
by or voted under the control of the benefited Director; or (b) the Corporation’s Board of Directors determines that the loan or guarantee benefits
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
and Treatment of Company Equity Awards;”
Eligibility of ImmunoGen’s executive officers to receive severance payments and benefits (including vesting … ; the benefits of the Merger; the Merger; the timing of and receipt of required regulatory filings and approvals relating to the transaction
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
and benefits (including vesting acceleration of any Company RSUs that may be granted following the date of the Merger Agreement) upon a termination … , performance, objectives and opportunities and the outlook for ImmunoGen’s business; the benefits of the Merger; the Merger; the timing of and receipt
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
on Linker.
COMPENSATION AND BENEFITS
Is the trading window still open and will approvals to trade be approved through the previously communicated date … benefits be affected?
Between now and the closing, your compensation and benefits will remain the same. The annual bonus for the fiscal year ending
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:08pm
this transaction and what it means for you:
All of your RSUs and options, vested or unvested, will be cashed out at closing.
All existing benefits … bonus that is at least as favorable as that provided to you at closing, as well as employee benefits that are at least as favorable in the aggregate
DEFA14A
EX-2.1
ciz7 q97lf
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-99.1
swdh q3q3
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
3uc8p
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
lq79bqw0n5 18r1tmv13
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
2byqrv8m
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
09cnboxmwtm6p
18 Sep 23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
6:35am
8-K
EX-99.1
m519 cq585gjysw
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-1.1
ul902ot88hdfr3tl
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
1b7lxn3w
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
dbdz6i
3 May 23
Prospectus supplement for primary offering
4:05pm